Bouzidi H, Daudon M
Faculté de pharmacie de Monastir, Tunisie.
Ann Biol Clin (Paris). 2007 Sep-Oct;65(5):473-81.
Cystinuria is an autosomal recessive disorder characterized by an impaired transport of cystine and dibasic aminoacids, lysine, arginine and ornithine in the proximal renal tubule and in the epithelial cells of the gastrointestinal tract. Recurrent cystine nephrolithiasis is the main clinical feature. Mutations in SLC3A1 and/or SLC7A9 genes, which are encoding respectively the rBAT and the b(0,+)AT proteins of the amino acid transport system, are responsible of this disorder thus inducing a high dibasic amino acid excretion. Diagnostic is based on stone analysis by infrared spectroscopy or microscopic examination of urine which may reveal typical cystine crystals. Quantitative cystine excretion, which may be assessed by aminoacid chromatography, is higher in cystinic patients. Molecular approach can identify mutations which are responsible of this pathology. Medical treatment is mainly based on hydratation and urine alkalinisation, with the addition of thiol derivative only in refractory cases. Follow-up based on pH and specific gravity determination in urine samples and cystine crystal volume measurement are used to optimally monitor the medical treatment of cystinuric patients. Even with medical management, long-term outcome is poor due to insufficient efficacy and low patient compliance. Many patients suffer from renal insufficiency as a result of recurrent stone formation and repeated surgical procedures.
胱氨酸尿症是一种常染色体隐性疾病,其特征是近端肾小管和胃肠道上皮细胞中胱氨酸及二碱基氨基酸(赖氨酸、精氨酸和鸟氨酸)的转运受损。复发性胱氨酸肾结石是主要临床特征。分别编码氨基酸转运系统的rBAT和b(0,+)AT蛋白的SLC3A1和/或SLC7A9基因突变是导致该疾病的原因,从而引起高浓度二碱基氨基酸排泄。诊断基于通过红外光谱法进行结石分析或对尿液进行显微镜检查,尿液检查可能会发现典型的胱氨酸晶体。胱氨酸患者的定量胱氨酸排泄量(可通过氨基酸色谱法评估)更高。分子检测方法能够识别导致这种病症的突变。医学治疗主要基于水化和尿液碱化,仅在难治性病例中添加硫醇衍生物。基于尿液样本的pH值和比重测定以及胱氨酸晶体体积测量的随访用于优化监测胱氨酸尿症患者的医学治疗。即便进行医学管理,由于疗效不佳和患者依从性低,长期预后也很差。许多患者因复发性结石形成和反复手术而出现肾功能不全。